Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
South Korea president says Iran war shows the need to ditch ‘extremely risky’ fossil fuels - 2Figure out What Shift Differentials Mean for Your General Attendant Compensation
- 3Nigeria’s return to Windsor castle signals new era in UK economic partnership
- 4Twins were the norm for our ancient primate ancestors − one baby at a time had evolutionary advantages
- 5Parents who delay baby's first vaccines also likely to skip measles shots
- Chinese astronauts’ return to Earth delayed over fears spaceship damaged by debris
- What to know about new CDC deputy director who has been critical of COVID vaccines
- Trump awarded 1st FIFA Peace Prize by Gianni Infantino at 2026 World Cup draw
- The Most Compelling Innovation Advancements Somewhat recently
- Von der Leyen: Paris meeting sends signal of unity for Ukraine
- In a scientific first, biologists recorded a wild wolf potentially using tools
- Remote Headphones: Upgrade Your Sound Insight
- 41 Young Men Die in South Africa After Circumcision Initiation
- Former biotech CEO sued over COVID vaccine alleged insider trading
